Fujimoto Pharmaceutical Group

Fujimoto Pharmaceutical Group is a specialized Japanese pharmaceutical organization focused on the development and supply of orphan drugs and niche therapeutic products. Headquartered in Osaka, the group gained significant prominence for its successful efforts in re-introducing thalidomide to the Japanese market under the brand name Thaled for the treatment of multiple myeloma. The company operates a vertically integrated model encompassing research, chemical synthesis, and drug manufacturing through its subsidiary, Fujimoto Chemical Co., Ltd. Their R&D efforts are currently concentrated on oncology and diagnostic imaging, particularly in the field of Boron Neutron Capture Therapy (BNCT) tracers. Fujimoto Pharmaceutical Group remains a private entity, maintaining a strong domestic presence while collaborating with international partners for specialty medicine distribution.